An Ji Yeong, Choi Yoon Young, Lee Jeeyun, Hyung Woo Jin, Kim Kyoung-Mee, Noh Sung Hoon, Choi Min-Gew, Cheong Jae-Ho
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Surgery, Yonsei University Health System, Seoul, Korea.
Cancer Res Treat. 2020 Oct;52(4):1153-1161. doi: 10.4143/crt.2020.173. Epub 2020 May 4.
High microsatellite instability (MSI) is related to good prognosis in gastric cancer. We aimed to identify the prognostic factors of patients with recurrent gastric cancer and investigate the role of MSI as a prognostic and predictive biomarker of survival after tumor recurrence.
This retrospective cohort study enrolled patients treated for stage II/III gastric cancer who developed tumor recurrence and in whom the MSI status or mismatch repair (MMR) status of the tumor was known. MSI status and the expression of MMR proteins were evaluated using polymerase chain reaction and immunohistochemical analysis, respectively.
Of the 790 patients included, 64 (8.1%) had high MSI status or MMR deficiency. The tumor-node-metastasis stage, type of recurrence, Lauren classification, chemotherapy after recurrence, and interval to recurrence were independently associated with survival after tumor recurrence. The MSI/MMR status and receiving adjuvant chemotherapy were not associated with survival after recurrence. In a subgroup analysis of patients with high MSI or MMR-deficient gastric cancer, those who did not receive adjuvant chemotherapy had better treatment response to chemotherapy after recurrence than those who received adjuvant chemotherapy.
Patients with high MSI/MMR-deficient gastric cancer should be spared from adjuvant chemotherapy after surgery, but aggressive chemotherapy after recurrence should be considered. Higher tumor-node-metastasis stage, Lauren classification, interval to recurrence, and type of recurrence are associated with survival after tumor recurrence and should thus be considered when establishing a treatment plan and designing clinical trials targeting recurrent gastric cancer.
高微卫星不稳定性(MSI)与胃癌的良好预后相关。我们旨在确定复发性胃癌患者的预后因素,并研究MSI作为肿瘤复发后生存的预后和预测生物标志物的作用。
这项回顾性队列研究纳入了接受II/III期胃癌治疗且出现肿瘤复发且已知肿瘤MSI状态或错配修复(MMR)状态的患者。分别使用聚合酶链反应和免疫组织化学分析评估MSI状态和MMR蛋白的表达。
在纳入的790例患者中,64例(8.1%)具有高MSI状态或MMR缺陷。肿瘤-淋巴结-转移分期、复发类型、劳伦分类、复发后化疗及复发间隔与肿瘤复发后的生存独立相关。MSI/MMR状态和接受辅助化疗与复发后的生存无关。在高MSI或MMR缺陷型胃癌患者的亚组分析中,未接受辅助化疗的患者复发后对化疗的治疗反应优于接受辅助化疗的患者。
高MSI/MMR缺陷型胃癌患者术后应避免辅助化疗,但应考虑复发后积极化疗。更高的肿瘤-淋巴结-转移分期、劳伦分类、复发间隔和复发类型与肿瘤复发后的生存相关,因此在制定治疗方案和设计针对复发性胃癌的临床试验时应予以考虑。